Company Stock: NASD:VSGN TSX: VAS
Website: vasogen.com
SEDAR Filings: sedar.com
Press Releases: vasogen.com
Product Pipeline: vasogen.com
Shares Outstanding: 72 million at March 4, 2004(fully diluted: 76 million)
Based on the competitive products listed in a biotech report, here's a link to Yahoo giving quotes/news for the companies involved in developing similar drugs to Vasogen's Celacade.
finance.yahoo.com
Here are the phases I think they're in based on PRs and info from the websites.
Vasogen's Celacade - Phase III est. comp Q2 2005
Atherogenics AGI-1067 - Phase III est. comp Q1 2006
GSK's Lp-PLA2 inhibitor - Phase II
DeCode's DG031 - Phase IIa - 2+ years out
Vertex's VX702 - Phase IIa
Incyte's INC3284 - Phase I |
